



REPORTED SALES vs. PRIOR PERIOD (\$MM)

CONSUMER SEGMENT ⁽²⁾

BABY CARE

	FOURTH QUARTER					TWELVE MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
US	103	103	0.0%	0.0%	-	418	409	2.2%	2.2%	-
Intl	465	474	-1.9%	0.7%	-2.6%	1,922	1,800	6.8%	3.4%	3.4%
WW	568	577	-1.6%	0.6%	-2.2%	2,340	2,209	5.9%	3.2%	2.7%

ORAL CARE

US	173	149	16.1%	16.1%	-	656	635	3.3%	3.3%	-
Intl	239	240	-0.4%	1.4%	-1.8%	968	891	8.6%	3.9%	4.7%
WW	412	389	5.9%	7.0%	-1.1%	1,624	1,526	6.4%	3.6%	2.8%

OTC/NUTRITIONALS

US	370	381	-2.9%	-2.9%	-	1,429	1,853	-22.9%	-22.9%	-
Intl	766	711	7.7%	8.7%	-1.0%	2,973	2,696	10.3%	5.2%	5.1%
WW	1,136	1,092	4.0%	4.6%	-0.6%	4,402	4,549	-3.2%	-6.2%	3.0%

SKIN CARE

US	403	352	14.5%	14.5%	-	1,654	1,537	7.6%	7.6%	-
Intl	541	537	0.7%	1.3%	-0.6%	2,061	1,915	7.6%	3.0%	4.6%
WW	944	889	6.2%	6.6%	-0.4%	3,715	3,452	7.6%	5.0%	2.6%

WOMEN'S HEALTH

US	89	118	-24.6%	-24.6%	-	439	522	-15.9%	-15.9%	-
Intl	309	332	-6.9%	-4.0%	-2.9%	1,353	1,322	2.3%	-1.5%	3.8%
WW	398	450	-11.6%	-9.5%	-2.1%	1,792	1,844	-2.8%	-5.5%	2.7%

WOUND CARE/OTHER

US	110	116	-5.2%	-5.2%	-	555	563	-1.4%	-1.4%	-
Intl	100	97	3.1%	6.2%	-3.1%	455	447	1.8%	-3.3%	5.1%
WW	210	213	-1.4%	-0.5%	-0.9%	1,010	1,010	0.0%	-2.3%	2.3%

TOTAL CONSUMER

US	1,248	1,219	2.4%	2.4%	-	5,151	5,519	-6.7%	-6.7%	-
Intl	2,420	2,391	1.2%	2.8%	-1.6%	9,732	9,071	7.3%	2.9%	4.4%
WW	3,668	3,610	1.6%	2.7%	-1.1%	14,883	14,590	2.0%	-0.7%	2.7%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT ^{(2) (4)}										
ACIPHEX/PARIET										
US	110	119	-7.6%	-7.6%	-	414	475	-12.8%	-12.8%	-
Intl	144	133	8.3%	8.7%	-0.4%	561	531	5.6%	0.0%	5.6%
WW	254	252	0.8%	1.0%	-0.2%	975	1,006	-3.1%	-6.1%	3.0%
CONCERTA/METHYLPHENIDATE										
US	155	261	-40.6%	-40.6%	-	822	929	-11.5%	-11.5%	-
Intl	119	107	-11.2%	11.6%	-0.4%	446	390	14.4%	8.7%	5.7%
WW	274	368	-25.5%	-25.4%	-0.1%	1,268	1,319	-3.9%	-5.6%	1.7%
DOXIL/CAELYX										
US	10	55	-81.8%	-81.8%	-	140	280	-50.0%	-50.0%	-
Intl	29	12	*	*	-10.3%	262	40	*	*	5.3%
WW	39	67	-41.8%	-34.1%	-7.7%	402	320	25.6%	22.1%	3.5%
DURAGESIC/FENTANYL TRANSDERMAL										
US	21	45	-53.3%	-53.3%	-	90	162	-44.4%	-44.4%	-
Intl	119	151	-21.2%	-21.9%	0.7%	499	586	-14.8%	-20.1%	5.3%
WW	140	196	-28.6%	-29.1%	0.5%	589	748	-21.3%	-25.5%	4.2%
LEVAQUIN/FLOXIN										
US	(6)	386	*	*	-	579	1,312	-55.9%	-55.9%	-
Intl	11	14	-21.4%	-17.7%	-3.7%	44	45	-2.2%	-3.7%	1.5%
WW	5	400	-98.8%	-98.7%	-0.1%	623	1,357	-54.1%	-54.2%	0.1%
PREZISTA										
US	143	111	28.8%	28.8%	-	529	401	31.9%	31.9%	-
Intl	173	125	38.4%	39.0%	-0.6%	682	456	49.6%	44.8%	4.8%
WW	316	236	33.9%	34.2%	-0.3%	1,211	857	41.3%	38.6%	2.7%
PROCRIT/EPREX										
US	191	270	-29.3%	-29.3%	-	814	1,070	-23.9%	-23.9%	-
Intl	177	209	-15.3%	-13.7%	-1.6%	809	864	-6.4%	-10.8%	4.4%
WW	368	479	-23.2%	-22.6%	-0.6%	1,623	1,934	-16.1%	-18.0%	1.9%
REMICADE										
US	776	679	14.3%	14.3%	-	3,276	3,099	5.7%	5.7%	-
US Exports ⁽³⁾	437	381	14.7%	14.7%	-	1,797	1,487	20.8%	20.8%	-
Intl	215	5	*	*	2.3%	419	24	*	*	4.8%
WW	1,428	1,065	34.1%	33.6%	0.5%	5,492	4,610	19.1%	18.7%	0.4%
RISPERDAL/RISPERIDONE										
US	7	2	*	*	-	34	(12)	*	*	-
Intl	141	149	-5.4%	-7.9%	2.5%	508	539	-5.8%	-11.6%	5.8%
WW	148	151	-2.0%	-4.4%	2.4%	542	527	2.8%	-3.1%	5.9%
RISPERDAL CONSTA										
US	108	105	2.9%	2.9%	-	443	445	-0.4%	-0.4%	-
Intl	277	283	-2.1%	-1.3%	-0.8%	1,140	1,055	8.1%	2.7%	5.4%
WW	385	388	-0.8%	-0.2%	-0.6%	1,583	1,500	5.5%	1.7%	3.8%
TOPAMAX										
US	40	37	8.1%	8.1%	-	176	199	-11.6%	-11.6%	-
Intl	81	84	-3.6%	-2.6%	-1.0%	312	339	-8.0%	-11.9%	3.9%
WW	121	121	0.0%	0.7%	-0.7%	488	538	-9.3%	-11.8%	2.5%
VELCADE										
US	-	-	-	-	-	-	-	-	-	-
Intl	352	287	22.6%	22.4%	0.2%	1,274	1,080	18.0%	12.7%	5.3%
WW	352	287	22.6%	22.4%	0.2%	1,274	1,080	18.0%	12.7%	5.3%
OTHER										
US	895	698	28.2%	28.2%	-	3,272	2,672	22.5%	22.5%	-
Intl	1,369	1,002	36.6%	36.0%	0.6%	5,026	3,928	28.0%	22.2%	5.8%
WW	2,264	1,700	33.2%	32.8%	0.4%	8,298	6,600	25.7%	22.2%	3.5%
TOTAL PHARMACEUTICAL										
US	2,887	3,149	-8.3%	-8.3%	-	12,386	12,519	-1.1%	-1.1%	-
Intl	3,207	2,561	25.2%	25.0%	0.2%	11,982	9,877	21.3%	15.5%	5.8%
WW	6,094	5,710	6.7%	6.6%	0.1%	24,368	22,396	8.8%	6.2%	2.6%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

MAJOR NEW PHARM PRODUCTS ⁽⁴⁾
(INCLUDED IN OTHER)

INTELENCE

	FOURTH QUARTER		
	2011	2010	Total % Change
US	45	34	32.4%
Intl	38	31	22.6%
WW	83	65	27.7%

INVEGA

	FOURTH QUARTER		
	2011	2010	Total % Change
US	66	70	-5.7%
Intl	59	46	28.3%
WW	125	116	7.8%

SIMPONI

	FOURTH QUARTER		
	2011	2010	Total % Change
US	62	56	10.7%
Intl	57	9	*
WW	119	65	83.1%

STELARA

	FOURTH QUARTER		
	2011	2010	Total % Change
US	126	73	72.6%
Intl	81	47	72.3%
WW	207	120	72.5%

	TWELVE MONTHS		
	2011	2010	Total % Change
INTELENCE	163	127	28.3%
INVEGA	285	270	5.6%
SIMPONI	235	193	21.8%
STELARA	443	240	84.6%
Subtotal	151	116	30.2%
Subtotal	314	243	29.2%
Subtotal	214	154	39.0%
Subtotal	499	424	17.7%
Subtotal	175	33	*
Subtotal	410	226	81.4%
Subtotal	295	153	92.8%
Subtotal	738	393	87.8%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational⁽¹⁾	Currency			Reported	Operational⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS⁽²⁾										
CARDIOVASCULAR CARE⁽⁵⁾										
US	191	246	-22.4%	-22.4%	-	841	1,008	-16.6%	-16.6%	-
Intl	349	383	-8.9%	-9.6%	0.7%	1,447	1,544	-6.3%	-11.4%	5.1%
WW	540	629	-14.1%	-14.5%	0.4%	2,288	2,552	-10.3%	-13.4%	3.1%
DEPUY										
US	775	807	-4.0%	-4.0%	-	3,093	3,145	-1.7%	-1.7%	-
Intl	678	640	5.9%	5.7%	0.2%	2,716	2,440	11.3%	5.0%	6.3%
WW	1,453	1,447	0.4%	0.3%	0.1%	5,809	5,585	4.0%	1.2%	2.8%
DIABETES CARE										
US	330	318	3.8%	3.8%	-	1,312	1,259	4.2%	4.2%	-
Intl	340	326	4.3%	4.4%	-0.1%	1,340	1,211	10.7%	5.7%	5.0%
WW	670	644	4.0%	4.1%	-0.1%	2,652	2,470	7.4%	5.0%	2.4%
ETHICON										
US	536	501	7.0%	7.0%	-	2,111	2,000	5.6%	5.6%	-
Intl	697	651	7.1%	7.6%	-0.5%	2,759	2,503	10.2%	5.0%	5.2%
WW	1,233	1,152	7.0%	7.3%	-0.3%	4,870	4,503	8.2%	5.3%	2.9%
ETHICON ENDO-SURGERY										
US	524	501	4.6%	4.6%	-	1,957	1,975	-0.9%	-0.9%	-
Intl	809	756	7.0%	6.3%	0.7%	3,123	2,783	12.2%	6.3%	5.9%
WW	1,333	1,257	6.0%	5.6%	0.4%	5,080	4,758	6.8%	3.4%	3.4%
ORTHO-CLINICAL DIAGNOSTICS										
US	280	276	1.4%	1.4%	-	1,091	1,091	0.0%	0.0%	-
Intl	274	260	5.4%	4.8%	0.6%	1,073	962	11.5%	5.9%	5.6%
WW	554	536	3.4%	3.1%	0.3%	2,164	2,053	5.4%	2.8%	2.6%
VISION CARE										
US	214	212	0.9%	0.9%	-	966	934	3.4%	3.4%	-
Intl	496	447	11.0%	8.2%	2.8%	1,950	1,746	11.7%	4.5%	7.2%
WW	710	659	7.7%	5.8%	1.9%	2,916	2,680	8.8%	4.1%	4.7%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS										
US	2,850	2,861	-0.4%	-0.4%	-	11,371	11,412	-0.4%	-0.4%	-
Intl	3,643	3,463	5.2%	4.6%	0.6%	14,408	13,189	9.2%	3.4%	5.8%
WW	6,493	6,324	2.7%	2.4%	0.3%	25,779	24,601	4.8%	1.7%	3.1%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported in U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Previously Cordis